Forensic Analysis · Consulting & Engineering Services · as of Nov 11, 2026

Neogenomics Inc (NEO)

A forensic read on Neogenomics Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

1.5

Distress distance

Clean

Earnings quality

Forensic signals

-12.4%

ROE

10.1%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Neogenomics Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 1.5, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-8.0%

FY2025

Return on invested capital. Return on invested capital is -8.0% in the latest fiscal year, against -6.9% in FY2023, having run between -8.0% and -6.0% across FY2023–FY2025 with no direction held. After-tax operating profit was ($85M) in FY2023 and ($92M) in FY2025, with operating income at -18.2% of revenue in FY2023, -13.9% in FY2024 and -15.9% in FY2025. The capital base behind it went from $1.2B in FY2023 to $1.1B in FY2025 (-8%), while the revenue it carried went from $592M to $727M.

$4M

FY2025

Goodwill impairments. Took $4M of goodwill writedowns across 1 year (FY2025 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$727.3M

Revenue Growth YoY+10.1%

Revenue CAGR (2yr)+10.9%

Net Margin-14.9%

Free Cash Flow-$21.8M

Return on Equity-12.4%

Debt / Equity0.41x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Neogenomics Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 11, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.